Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 28;13(1):100.
doi: 10.1038/s41408-023-00874-y.

Cost comparison of post-remission strategies in younger and older AML patients in France

Michael Mounie  1   2 , Pierre-Yves Dumas  3   4   5 , Sandra Liva-Yonnet  6 , Didier Fabre  6 , Thibault Leguay  3 , Jean Galtier  3 , Emilie Berard  7 , Ramaroson Hanta  8 , Véronique Gilleron  8 , Sarah Bertoli  9   10   11 , Arnaud Pigneux  4   5 , Christian Récher  12   13   14 , Nadège Costa  15   7
Affiliations

Cost comparison of post-remission strategies in younger and older AML patients in France

Michael Mounie et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

CR: report grants, personal fees, and non-financial support from Abbvie; grants from Amgen; grants, personal fees, and non-financial support from Astellas; grants, personal fees, and non-financial support from BMS; grants, personal fees, and non-financial support from Jazz Pharmaceuticals; grants from Iqvia; personal fees and non-financial support from Novartis; grants from MaatPharma; personal fees and non-financial support from Servier; and personal fees from Takeda. P-YD: Daiichi-Sankyo, Jazz Pharmaceutical, Astellas, Abbvie, Celgene, and Janssen. Sarah Bertoli: Jazz Pharmaceuticals, Daiichi-Sankyo, Sanofi, Astellas, BMS, Abbvie, and Pfizer. Arnaud Pigneux: Grant/Research Support: Astellas and Roches; Speaker’s Bureau: AbbVie, Astellas, Gilead, Pfizer, Roche, and Sanofi; Consultant: AbbVie, Agios, BMS, Gilead, Jazz Pharma, Novartis, Pfizer, Roche, and Takeda.

References

    1. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896–903. doi: 10.1056/NEJM199410063311402. - DOI - PubMed
    1. Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013;121:26–8. doi: 10.1182/blood-2012-07-444851. - DOI - PubMed
    1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. doi: 10.1182/blood.2022016867. - DOI - PubMed
    1. Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, et al. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J. 2017;7:e564. doi: 10.1038/bcj.2017.45. - DOI - PMC - PubMed
    1. Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, et al. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. Blood Adv. 2020;4:3840–9. doi: 10.1182/bloodadvances.2020002511. - DOI - PMC - PubMed